← Back to Search

DNA Methyltransferase Inhibitor

DSP107 + Azacitidine/Venetoclax for Leukemia

Phase 1
Recruiting
Research Sponsored by Kahr Medical
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Relapsed/refractory AML or MDS/CMML patients who have failed up to 2 prior therapeutic regimens
Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
Must not have
Treatment with any CD47/SIRPα targeting agent or immune agonists
Known allergy or hypersensitivity to any of the test compounds, materials or contraindication to test product
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at the end of treatment cycle 2 (within 2 months of treatment initiation)
Awards & highlights
No Placebo-Only Group

Summary

This trial will enroll patients with relapsed/refractory AML or MDS/chronic myelomonocytic leukemia (CMML) who have failed up to 2 prior therapeutic regimens. Part A is a dose escalation study of a new drug, DSP107, given alone and with azacitidine. Part B is a dose escalation study of DSP107 given with azacitidine and venetoclax.

Who is the study for?
This trial is for patients with certain blood cancers like AML, MDS, or CMML who have tried and failed up to two treatments. They should have a white blood cell count under a specific limit, decent organ function, and be in fair to good physical condition (ECOG 0-2). It's not for those with severe liver disease, recent immunostimulatory treatment, active hepatitis B or C infection, lung issues, pregnancy/breastfeeding intentions during the study period.
What is being tested?
The trial tests DSP107 combined with azacitidine (AZA) in Part A and adds venetoclax (VEN) in Part B. Both parts aim to find safe doses while checking how well these combinations work against the cancer by monitoring their effects on the body and cancer cells.
What are the potential side effects?
Potential side effects of DSP107 include reactions related to immune system activation which could affect various organs. Azacitidine may cause nausea or low blood counts leading to fatigue or infections. Venetoclax can also lower blood counts and might lead to tiredness or bleeding complications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My AML or MDS/CMML has not improved after up to 2 treatments.
Select...
I can take care of myself and am up and about more than 50% of my waking hours.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have not been treated with drugs targeting CD47/SIRPα or immune boosters.
Select...
I am not allergic to any of the materials or drugs used in the test.
Select...
I am experiencing symptoms of graft versus host disease.
Select...
I do not have an active Hepatitis B or C infection.
Select...
I have been diagnosed with acute promyelocytic leukemia.
Select...
I stopped previous immunotherapy due to a severe reaction.
Select...
I have a history of severe lung issues.
Select...
My leukemia is affecting my brain and causing symptoms.
Select...
I have had an organ transplant and am on immunosuppressants.
Select...
I had a severe reaction to previous immunotherapy.
Select...
My liver is not working well and it affects my health significantly.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at the end of treatment cycle 2 (within 2 months of treatment initiation)
This trial's timeline: 3 weeks for screening, Varies for treatment, and at the end of treatment cycle 2 (within 2 months of treatment initiation) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Adverse Events (AEs)
Dose Limiting Toxicities (DLT)
Response Rate (RR) including Complete Remission (CR) and Complete Remission with Incomplete Blood Count Recovery (CRi)
Secondary study objectives
4-week Mortality Rate
Change in Phenotypic and Activation Profiles of Peripheral Blood Mononuclear Cells
DSP107 Serum Concentration
+4 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: DSP107 in combination with azacitidine or azacitidine plus venetoclax.Experimental Treatment3 Interventions
DSP107 will be administered by intravenous infusion once weekly during each 28-day cycle to all patients in this study. Azacitidine (75 mg/m2/day) will be administered subcutaneously or intravenously for the first 7 days of every cycle. Patients enrolled in Part B only will also receive venetoclax. During Cycle 1, venetoclax will be dose escalated daily to the goal dose of 400 mg daily. Patients will receive 100 mg on Day 1, 200 mg on Day 2 and 400 mg on Day 3 and onwards.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Azacitidine
2012
Completed Phase 3
~1440
Venetoclax
2019
Completed Phase 3
~2240

Find a Location

Who is running the clinical trial?

Kahr MedicalLead Sponsor
2 Previous Clinical Trials
125 Total Patients Enrolled

Media Library

Azacitidine (DNA Methyltransferase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04937166 — Phase 1
Acute Myeloid Leukemia Research Study Groups: DSP107 in combination with azacitidine or azacitidine plus venetoclax.
Acute Myeloid Leukemia Clinical Trial 2023: Azacitidine Highlights & Side Effects. Trial Name: NCT04937166 — Phase 1
Azacitidine (DNA Methyltransferase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04937166 — Phase 1
~5 spots leftby Jun 2025